Kaitlin Annunzio, DO, MS

Publications

• Outcomes of bispecific antibodies after CAR T-cell failure for large B-cell lymphoma: results from the ABC consortium.

  (Melody M, Grover N, Franco S, Romancik J, Cortese M, Moyo TK, Bhansali RS, Ollila T, Kenkre V, Fitzgerald L, Hess B, Matasar M, Shouse G, Annunzio K, Herr MM, Davis JA, Jesme C, Pelcovits A, Moreira J, Ma S, Winter JN, Lin A, Danilov A, Roy I, Barta SK, Gordon LI, Stephens D, Cohen JB, Epperla N, Karmali R.) Blood Adv. 2026 Jan 13;10(1):228-232 PMID: 41124653 PMCID: PMC12811448 10/22/2025

• Sequencing CAR-Ts in Relapsed DLBCL: Is More Always Better?

  (Annunzio K, Shah NN.) Transplant Cell Ther. 2025 Nov;31(11):849-850 PMID: 41176372 SCOPUS ID: 2-s2.0-105020044401 11/02/2025

• Impact of extranodal involvement at CAR T-cell therapy on outcomes in patients with relapsed or refractory large B-cell lymphoma-Results from a multicenter cohort study.

  (St-Pierre F, Bhatta S, Doukas PG, Jenkin M, Annunzio K, Rojek AE, Gibson A, Tiger YK, McCall B, Alhamad K, Hansen A, Alderuccio JP, Adewale O, Patel K, Trabolsi A, Lossos IS, Fitzgerald L, Ollila TA, Matasar MJ, Kline J, Karmali R, Epperla N.) Blood Cancer J. 2025 Jun 21;15(1):110 PMID: 40544154 PMCID: PMC12182562 06/22/2025

• Impact of diagnosis to treatment interval on outcomes in patients with newly diagnosed marginal zone lymphoma - a US multisite study.

  (Epperla N, Shouse G, Grover NS, Torka P, Annunzio K, Watkins M, Anampa-Guzmán A, Christian B, Thomas C, Barta SK, Geethakumari PR, Karmali R, Bartlett NL, Olszewski AJ.) Exp Hematol Oncol. 2025 May 14;14(1):73 PMID: 40369604 PMCID: PMC12079943 05/15/2025

• Impact of Age on Biology, Presentation and Outcomes in Marginal Zone Lymphoma: Results From a Multicenter Cohort Study.

  (Torka P, Grover NS, Voorhees TJ, Karmali R, Annunzio K, Watkins MP, Anampa-Guzmán A, Reves H, Tavakkoli M, Christian B, Thomas C, Barta SK, Geethakumari PR, Bartlett NL, Shouse G, Olszewski AJ, Epperla N.) Hematol Oncol. 2025 May;43(3):e70087 PMID: 40260947 PMCID: PMC12013245 04/22/2025

• Chimeric antigen receptor T cell therapy in octogenarians with B cell lymphoma: a real-world US multicenter collaborative study.

  (Kharfan-Dabaja MA, Mohty R, Easwar N, Johnston P, Iqbal M, Epperla N, Yared J, Ahmed N, Hamadani M, Beitinjaneh A, Narkhede M, Jagadeesh D, Ramakrishnan Geethakumari P, Dholaria B, Gergis U, Munoz J, Sandoval-Sus J, Locke FL, Fein J, Khurana A, Ayala E, Annunzio K, Rapoport AP, Lutfi F, Akhtar OS, Lekakis L, Mehta A, Oluwole OO, Logue J, Jain MD, Shore T, Durani U, Alhaj Moustafa M, McGuirk J, Lin Y, Yamshon S, Chavez JC.) Bone Marrow Transplant. 2025 May;60(5):632-639 PMID: 40025178 03/03/2025

• Loncastuximab in high-risk and heavily pretreated relapsed/refractory diffuse large B-cell lymphoma: a realworld analysis from 21 US centers.

  (Zelikson V, Gurumurthi A, Sawalha Y, Annunzio K, Saha A, Dong N, Qualls D, Amoozgar B, Kahl B, Baird J, Challa P, Huntington SF, Santos J, Bair S, Narkhede M, Li S, Frosch Z, Ho C, Smith SD, Winter A, Landsburg D, Furqan F, Hamadani M, Baird K, Romancik J, Alharthy H, Law J, Bojanini L, Advani R, Hu B, Johnson PC, Grover NS, Merril M, Crombie JL, Shafagati N, Sterling C, Nastoupil LJ, Epperla N, Ayers EC.) Haematologica. 2025 Mar 01;110(3):706-714 PMID: 39540227 PMCID: PMC11873705 11/14/2024

• Outcomes of follicular lymphoma with leukemic phase in the modern era: results from a large multicenter study.

  (Trabolsi A, Han S, Epperla N, Annunzio K, Baidoun F, Alhaj Moustafa M, Morgenstern-Kaplan D, Doukas P, St-Pierre F, McCall B, Fitzgerald L, Sandoval-Sus J, Dalal S, Reis IM, Chapman-Fredricks JR, Kim SH, Au C, Otto NB, Alhamad K, Ollila T, Karmali R, Shouse G, Lossos IS, Alderuccio JP.) Blood Neoplasia. 2025 Feb;2(1):100063 PMID: 40454403 PMCID: PMC12082143 06/02/2025

• Impact of circulating lymphoma cells at diagnosis on outcomes in patients with newly diagnosed de novo diffuse large B-cell lymphoma.

  (Chowdhury SM, Bhatta S, Voorhees TJ, Annunzio K, Bond DA, Sawalha Y, Sigmund A, Hanel W, Sehgal L, Alinari L, Baiocchi R, Maddocks K, Christian B, Jones D, Epperla N.) J Hematol Oncol. 2025 Jan 05;18(1):4 PMID: 39757235 PMCID: PMC11702192 01/06/2025

• Evaluation of Ki-67 expression and large cell content as prognostic markers in MZL: a multicenter cohort study.

  (Grover NS, Annunzio K, Watkins M, Torka P, Karmali R, Anampa-Guzmán A, Oh TS, Reves H, Tavakkoli M, Hansinger E, Christian B, Thomas C, Barta SK, Geethakumari PR, Bartlett NL, Shouse G, Olszewski AJ, Epperla N.) Blood Cancer J. 2024 Oct 18;14(1):182 PMID: 39424808 PMCID: PMC11489653 10/19/2024

• Impact of race and social determinants of health on outcomes in patients with aggressive B-cell NHL treated with CAR-T therapy.

  (Karmali R, Machhi R, Epperla N, Shouse G, Romancik J, Moyo TK, Kenkre V, Ollila TA, Fitzgerald L, Hess B, David K, Roy I, Zurko J, Chowdhury SM, Annunzio K, Ferdman R, Bhansali RS, Harris EI, Liu J, Nizamuddin I, Ma S, Moreira J, Winter J, Pro B, Stephens DM, Danilov A, Shah NN, Cohen JB, Barta SK, Torka P, Gordon LI.) Blood Adv. 2024 May 28;8(10):2592-2599 PMID: 38531057 PMCID: PMC11145749 SCOPUS ID: 2-s2.0-85195045599 03/26/2024

• Prognostic relevance of circulating lymphoma cells at diagnosis in newly diagnosed follicular lymphoma patients.

  (Annunzio K, Bhatta S, Hanel W, Zhao Q, Owen M, Rosen H, Voorhees TJ, Bond DA, Sawalha Y, Sigmund AM, Alinari L, Baiocchi RA, Maddocks KJ, Jones D, Christian B, Epperla N.) Hematol Oncol. 2024 May;42(3):e3278 PMID: 38726682 05/10/2024